HRP20201900T1 - Terapeutski i dijagnostički postupci kod raka - Google Patents
Terapeutski i dijagnostički postupci kod raka Download PDFInfo
- Publication number
- HRP20201900T1 HRP20201900T1 HRP20201900TT HRP20201900T HRP20201900T1 HR P20201900 T1 HRP20201900 T1 HR P20201900T1 HR P20201900T T HRP20201900T T HR P20201900TT HR P20201900 T HRP20201900 T HR P20201900T HR P20201900 T1 HRP20201900 T1 HR P20201900T1
- Authority
- HR
- Croatia
- Prior art keywords
- tumor
- binding antagonist
- expression
- patient
- level
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 29
- 238000002560 therapeutic procedure Methods 0.000 title claims 3
- 201000011510 cancer Diseases 0.000 title 1
- 238000002405 diagnostic procedure Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 38
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 38
- 239000005557 antagonist Substances 0.000 claims 21
- 230000014509 gene expression Effects 0.000 claims 19
- 238000000034 method Methods 0.000 claims 18
- 210000002865 immune cell Anatomy 0.000 claims 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 6
- 210000004881 tumor cell Anatomy 0.000 claims 5
- 238000003753 real-time PCR Methods 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229950009791 durvalumab Drugs 0.000 claims 2
- 238000003364 immunohistochemistry Methods 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 238000003196 serial analysis of gene expression Methods 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims 1
- 238000003559 RNA-seq method Methods 0.000 claims 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 claims 1
- 102000006381 STAT1 Transcription Factor Human genes 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 238000010166 immunofluorescence Methods 0.000 claims 1
- 238000007901 in situ hybridization Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 238000010208 microarray analysis Methods 0.000 claims 1
- 210000000651 myofibroblast Anatomy 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000010839 reverse transcription Methods 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Claims (15)
1. Antagonist vezanja PD-L1, naznačen time, što se upotrebljava u liječenju pacijenta koji pati od raka pluća ne-malih stanica, gdje je utvrđeno da uzorak tumora dobiven od pacijenta ima uočljivu razinu ekspresije PD-L1 u 50 % ili više tumorskih stanica u uzorku tumora, a pri čemu je antagonist vezanja PD-L1 jedno protutijelo.
2. Antagonist vezanja PD-L1 za uporabu u skladu s patentnim zahtjevom 1, naznačen time, što uzorak tumora dobiven od pacijenta ima uočljivu razinu ekspresije PD-L1 u imunološkim stanicama koje se infiltriraju u tumor i sadrže manje od 10 % uzorka.
3. Antagonist vezanja PD-L1 za uporabu u skladu s patentnim zahtjevom 1 ili 2, naznačen time, što je antagonist vezanja PD-L1 formuliran za uporabu u kombinaciji s drugim terapeutskim sredstvom, pri čemu je drugo terapeutsko sredstvo, neobvezno, odabrano iz skupine koja se sastoji od citotoksičnog sredstva, sredstva za inhibiciju rasta, sredstva za terapiju zračenjem, anti-angiogenog sredstva i njihovih kombinacija.
4. Postupak za (i) utvrđivanje vjerojatnosti da će pacijent koji boluje od raka pluća ne-malih stanica odgovoriti na liječenje koje sadrži antagonist vezanja PD-L1 ili (ii) predviđanje reakcije pacijenta koji pati od raka pluća ne-malih stanica na liječenje koje sadrži antagonist vezanja PD-L1, naznačen time, što taj postupak obuhvaća:
određivanje razine ekspresije PD-L1 u tumorskim stanicama u uzorku tumora dobivenom od pacijenta,
pri čemu prepoznatljiva razina ekspresije PD-L1 u 50 % ili više tumorskih stanica u uzorku tumora ukazuje na to da će pacijent vjerojatno odgovoriti na liječenje koje sadrži antagonist vezanja PD-L1, i pri čemu je antagonist vezanja PD-L1 jedno protutijelo.
5. Postupak u skladu s patentnim zahtjevom 4, naznačen time, što postupak nadalje obuhvaća određivanje razine ekspresije PD-L1 u imunološkim stanicama koje se infiltriraju u tumor u uzorku tumora dobivenom od pacijenta, pri čemu, neobvezno:
uzorak tumora dobiven od pacijenta ima uočljivu razinu ekspresije PD-L1 u imunološkim stanicama koje se infiltriraju u tumor i obuhvaćaju manje od 10 % uzorka; ili
je utvrđeno da uzorak tumora dobiven od pacijenta ima uočljivu razinu ekspresije PD-L1 u imunološkim stanicama koje se infiltriraju u tumor i obuhvaćaju 10 % ili više uzorka tumora.
6. Postupak za odabir terapije za pacijenta koji pati od raka pluća ne-malih stanica, naznačen time, što postupak obuhvaća:
određivanje razine ekspresije PD-L1 u tumorskim stanicama u uzorku tumora dobivenom od pacijenta, i
odabir terapije koja sadrži antagonist vezanja PD-L1 za pacijenta na temelju uočljive razine ekspresije PD-L1 u 50 % ili više tumorskih stanica u uzorku tumora, pri čemu je antagonist vezanja PD-L1 jedno protutijelo.
7. Postupak u skladu s patentnim zahtjevom 6, naznačen time, što postupak nadalje obuhvaća određivanje razine ekspresije PD-L1 u imunološkim stanicama koje se infiltriraju u tumor u uzorku tumora dobivenom od pacijenta, pri čemu uzorak tumora dobiven od pacijenta, neobvezno, ima uočljivu razinu ekspresije PD -L1 u imunološkim stanicama koje se infiltriraju u tumor i obuhvaćaju manje od 10 % uzorka.
8. Antagonist vezanja PD-L1 za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili postupak u skladu s bilo kojim patentnim zahtjevom od 4 do 7, naznačen time, što:
(i) uzorak tumora dobiven od pacijenta obuhvaća populaciju fibroblasta i/ili miofibroblasta;
(ii) uzorak tumora dobiven od pacijenta sadrži stromu siromašnu stanicama i/ili kolageniziranu stromu; i/ili
(iii) uzorak tumora ima povećanu razinu ekspresije kolagena, STAT1 ili MEK u odnosu na referentni uzorak tumora.
9. Antagonist vezanja PD-L1 za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3 i 8, ili postupak u skladu s bilo kojim od patentnih zahtjeva 4 do 8, naznačen time, što antagonist vezanja PD-L1 inhibira vezanje PD-L1 na jedan ili više njegovih partnera za vezanje liganda, pri čemu antagonist vezanja PD-L1, neobvezno, inhibira vezanje PD-L1 na PD-1, B7-1 ili na oba, PD-1 i B7-1.
10. Antagonist vezanja PD-L1 za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, 8 i 9, ili postupak u skladu s bilo kojim od patentnih zahtjeva 4 do 9, naznačen time, što je protutijelo odabrano iz skupine koja se sastoji od: MPDL3280A (atezolizumaba), MDX-1105, MEDI4736 (durvalumaba) i MSB0010718C (avelumaba).
11. Antagonist vezanja PD-L1 za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3 i 8 do 10, ili postupak u skladu s bilo kojim od patentnih zahtjeva 4 do 10, naznačen time, što protutijelo sadrži teški lanac koji sadrži HVR-H1 slijed od SEQ ID NO. 19, HVR-H2 slijed od SEQ ID NO. 20, i HVR- H3 slijed od SEQ ID NO. 21; i laki lanac koji sadrži HVR-L1 slijed od SEQ ID NO. 22, HVR-L2 slijed od SEQ ID NO. 23, i HVR-L3 slijed od SEQ ID NO. 24.
12. Antagonist vezanja PD-L1 za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3 i 8 do 11, ili postupak u skladu s bilo kojim od patentnih zahtjeva 4 do 11, naznačen time, što protutijelo sadrži varijabilno područje teškog lanca koje sadrži aminokiselinski slijed od SEQ ID NO. 25 te varijabilno područje lakog lanca koje sadrži aminokiselinski slijed od SEQ ID NO. 4.
13. Antagonist vezanja PD-L1 za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3 i 8 do12, ili postupak u skladu s bilo kojim od patentnih zahtjeva 4 do 12, naznačen time, što je rak pluća ne-malih stanica lokalno uznapredovali ili metastatski rak pluća ne-malih stanica,
14. Antagonist vezivanja PD-L1 za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3 i od 8 do 13, ili postupak u skladu s bilo kojim od patentnih zahtjeva 4 do 13, naznačen time, što je uzorak tumora tumorski uzorak koji je fiksiran u formalinu i ukalupljen u parafinu (FFPE), arhivski uzorak tumora, uzorak svježeg tumora ili uzorak smrznutog tumora.
15. Antagonist vezanja PD-L1 za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do3 i 8 do 14, ili postupak u skladu s bilo kojim od patentnih zahtjeva 4 do 14, naznačen time, što:
(i) razina ekspresije PD-L1 je razina ekspresije proteina, pri čemu se, neobvezno, razina ekspresije proteina PD-L1 određuje uporabom postupka odabranog iz skupine koja se sastoji od imunohistokemije (IHC), imunofluorescencije, protočne citometrije i Western blot-a; pri čemu se nadalje, neobvezno, razina ekspresije proteina PD-L1 otkriva korištenjem anti-PD-L1 protutijela; ili
(ii) razina ekspresije PD-L1 je razina ekspresije mRNA, pri čemu se, neobvezno, razina ekspresije mRNA od PD-L1 određuje uporabom postupka odabranog iz skupine koja se sastoji od kvantitativne lančane reakcije polimeraze (qPCR), reverzne transkripcije qPCR (RT-qPCR), RNA sekvenciranja, analize mikromreža, hibridizacije in situ i serijske analize ekspresije gena (SAGE).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562160561P | 2015-05-12 | 2015-05-12 | |
US201562168700P | 2015-05-29 | 2015-05-29 | |
EP16724821.0A EP3294770B2 (en) | 2015-05-12 | 2016-05-12 | Therapeutic and diagnostic methods for cancer |
PCT/US2016/032112 WO2016183326A1 (en) | 2015-05-12 | 2016-05-12 | Therapeutic and diagnostic methods for cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20201900T1 true HRP20201900T1 (hr) | 2021-01-22 |
Family
ID=56072467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20201900TT HRP20201900T1 (hr) | 2015-05-12 | 2020-11-27 | Terapeutski i dijagnostički postupci kod raka |
Country Status (19)
Country | Link |
---|---|
US (2) | US20180030138A1 (hr) |
EP (2) | EP3294770B2 (hr) |
JP (2) | JP7048319B2 (hr) |
KR (1) | KR20180008449A (hr) |
CN (1) | CN107667119A (hr) |
AU (2) | AU2016262074A1 (hr) |
CA (1) | CA2983282A1 (hr) |
DK (1) | DK3294770T3 (hr) |
ES (1) | ES2835866T3 (hr) |
HK (1) | HK1250376A1 (hr) |
HR (1) | HRP20201900T1 (hr) |
HU (1) | HUE051815T2 (hr) |
IL (2) | IL255312B (hr) |
LT (1) | LT3294770T (hr) |
MX (2) | MX2017014381A (hr) |
PT (1) | PT3294770T (hr) |
RS (1) | RS61152B1 (hr) |
SI (1) | SI3294770T1 (hr) |
WO (1) | WO2016183326A1 (hr) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10301273B2 (en) | 2014-08-07 | 2019-05-28 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
IL292449B2 (en) | 2015-03-13 | 2024-02-01 | Cytomx Therapeutics Inc | Nucleic acids encoding antibodies against PDL1 and methods for their preparation |
WO2016183326A1 (en) | 2015-05-12 | 2016-11-17 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
US10695400B2 (en) | 2015-08-03 | 2020-06-30 | Enb Therapeutics, Inc. | Compositions and methods for treating cancers associated with ETBR activation |
KR20180097615A (ko) | 2016-01-08 | 2018-08-31 | 에프. 호프만-라 로슈 아게 | Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법 |
WO2018097166A1 (ja) * | 2016-11-24 | 2018-05-31 | 第一三共株式会社 | Pd-1免疫チェックポイント阻害剤による治療に対するがんの感受性を予測する方法 |
WO2018129331A1 (en) * | 2017-01-07 | 2018-07-12 | Merck Patent Gmbh | Dosing regimens and dosage forms for targeted tgf-b inhibition |
AU2018211064A1 (en) * | 2017-01-18 | 2019-09-05 | Genentech, Inc. | Idiotypic antibodies against anti-PD-L1 antibodies and uses thereof |
WO2018151601A1 (en) * | 2017-02-17 | 2018-08-23 | Stichting Vumc | Swarm intelligence-enhanced diagnosis and therapy selection for cancer using tumor- educated platelets |
US11596629B2 (en) | 2017-02-28 | 2023-03-07 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
MX2019010295A (es) | 2017-03-01 | 2019-11-21 | Genentech Inc | Métodos de diagnóstico y terapéuticos para el cáncer. |
KR20200016899A (ko) | 2017-06-01 | 2020-02-17 | 싸이톰스 테라퓨틱스, 인크. | 활성화가능 항-pdl1 항체, 및 이의 이용 방법 |
AU2018304458B2 (en) | 2017-07-21 | 2021-12-09 | Foundation Medicine, Inc. | Therapeutic and diagnostic methods for cancer |
US10269803B2 (en) * | 2017-08-31 | 2019-04-23 | Taiwan Semiconductor Manufacturing Company, Ltd. | Hybrid scheme for improved performance for P-type and N-type FinFETs |
EP3713571A4 (en) | 2018-01-12 | 2021-08-25 | ENB Therapeutics, Inc. | DEUTERATED COMPOUNDS, COMPOSITIONS AND TREATMENT METHODS FOR CANCERS ASSOCIATED WITH ETBR ACTIVATION |
EP3752528A4 (en) * | 2018-02-17 | 2021-11-03 | Apollomics Inc. | CANCER TREATMENT USING A COMBINATION OF A NEUTROPHIL MODULATOR WITH AN IMMUNE CHECKPOINT MODULATOR |
US11243207B2 (en) | 2018-03-29 | 2022-02-08 | Mayo Foundation For Medical Education And Research | Assessing and treating cancer |
WO2019207030A1 (en) * | 2018-04-26 | 2019-10-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer |
JP2021524744A (ja) * | 2018-05-21 | 2021-09-16 | ナノストリング テクノロジーズ,インコーポレイティド | 分子遺伝子シグネチャーとその使用方法 |
KR20210034622A (ko) * | 2018-07-18 | 2021-03-30 | 제넨테크, 인크. | Pd-1 축 결합 길항제, 항 대사제, 및 백금 제제를 이용한 폐암 치료 방법 |
KR102084196B1 (ko) * | 2018-08-29 | 2020-03-03 | 연세대학교 산학협력단 | 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트 |
EP3857230B1 (en) | 2018-09-21 | 2023-06-07 | F. Hoffmann-La Roche AG | Diagnostic methods for triple-negative breast cancer |
CA3116324A1 (en) | 2018-10-18 | 2020-04-23 | Genentech, Inc. | Diagnostic and therapeutic methods for sarcomatoid kidney cancer |
WO2020135415A1 (zh) * | 2018-12-24 | 2020-07-02 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
CN111973739B (zh) * | 2019-05-23 | 2024-02-13 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
CN112805566A (zh) * | 2019-07-29 | 2021-05-14 | 上海谷森医药有限公司 | 用于吸入治疗肺癌的抗体类药物制剂 |
EP3792632A1 (en) * | 2019-09-16 | 2021-03-17 | Vito NV | Immunotherapy markers |
JP2023511595A (ja) | 2020-01-27 | 2023-03-20 | ジェネンテック, インコーポレイテッド | 抗tigitアンタゴニスト抗体を用いたがんを処置するための方法 |
CN115698717A (zh) * | 2020-04-03 | 2023-02-03 | 基因泰克公司 | 癌症的治疗和诊断方法 |
CA3181820A1 (en) | 2020-06-16 | 2021-12-23 | Genentech, Inc. | Methods and compositions for treating triple-negative breast cancer |
JP2024516230A (ja) | 2021-04-30 | 2024-04-12 | ジェネンテック, インコーポレイテッド | がんのための治療及び診断方法並びに組成物 |
WO2023019129A1 (en) * | 2021-08-10 | 2023-02-16 | Apexigen, Inc. | Biomarkers for cd40 agonist therapy |
WO2023220703A1 (en) | 2022-05-12 | 2023-11-16 | Genentech, Inc. | Methods and compositions comprising a shp2 inhibitor and a pd-l1 binding antagonist |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
Family Cites Families (140)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
WO1991003489A1 (en) | 1989-09-08 | 1991-03-21 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2050918A1 (en) | 1990-01-12 | 1991-07-13 | Raju Kucherlapati | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
ATE419355T1 (de) | 1992-02-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Marker für krebs und biosynthetisches bindeprotein dafür |
DK0669836T3 (da) | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
PT659439E (pt) | 1993-12-24 | 2002-04-29 | Merck Patent Gmbh | Imunoconjugados |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
KR100654645B1 (ko) | 1995-04-27 | 2007-04-04 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
EP0831880A4 (en) | 1995-06-07 | 2004-12-01 | Imclone Systems Inc | ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
CA2224435C (en) | 1995-07-06 | 2008-08-05 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
JP3370340B2 (ja) | 1996-04-12 | 2003-01-27 | ワーナー―ランバート・コンパニー | チロシンキナーゼの不可逆的阻害剤 |
ATE227283T1 (de) | 1996-07-13 | 2002-11-15 | Glaxo Group Ltd | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
PT980244E (pt) | 1997-05-06 | 2003-10-31 | Wyeth Corp | Utilizacao de compostos de quinazolina para o tratamento da doenca policistica renal |
JP2002506353A (ja) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | ガラクトシル化糖タンパク質の方法及び組成物 |
ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
AU1308799A (en) | 1997-11-06 | 1999-05-31 | American Cyanamid Company | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
PT1034298E (pt) | 1997-12-05 | 2012-02-03 | Scripps Research Inst | Humanização de anticorpo murino |
DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
WO2000031048A1 (en) | 1998-11-19 | 2000-06-02 | Warner-Lambert Company | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
EP2386574A3 (en) | 1999-01-15 | 2012-06-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
DK2270147T4 (da) | 1999-04-09 | 2020-08-31 | Kyowa Kirin Co Ltd | Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle |
AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
AU784983B2 (en) | 1999-12-15 | 2006-08-17 | Genentech Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
CA2395660A1 (en) | 1999-12-29 | 2001-07-12 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
ES2651952T3 (es) | 2000-10-06 | 2018-01-30 | Kyowa Hakko Kirin Co., Ltd. | Células que producen unas composiciones de anticuerpo |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス,インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES |
KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
EP1500400A4 (en) | 2002-04-09 | 2006-10-11 | Kyowa Hakko Kogyo Kk | MEDICAMENT WITH ANTIBODY COMPOSITION |
WO2003085107A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cellules à génome modifié |
AU2003236015A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition |
EP1500698B1 (en) | 2002-04-09 | 2011-03-30 | Kyowa Hakko Kirin Co., Ltd. | Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA |
EP1502603A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM |
CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
PT1572744E (pt) | 2002-12-16 | 2010-09-07 | Genentech Inc | Variantes de imunoglobulina e utilizações destas |
AU2004205631A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
EP1688439A4 (en) | 2003-10-08 | 2007-12-19 | Kyowa Hakko Kogyo Kk | HYBRID PROTEIN COMPOSITION |
EP1705251A4 (en) | 2003-10-09 | 2009-10-28 | Kyowa Hakko Kirin Co Ltd | PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE |
EP1692182B1 (en) | 2003-11-05 | 2010-04-07 | Roche Glycart AG | Cd20 antibodies with increased fc receptor binding affinity and effector function |
PT2489364E (pt) | 2003-11-06 | 2015-04-16 | Seattle Genetics Inc | Compostos de monometilvalina conjugados com anticorpos |
WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
RU2386638C2 (ru) | 2004-03-31 | 2010-04-20 | Дженентек, Инк. | Гуманизированные анти-тфр-бета-антитела |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
ES2403055T3 (es) | 2004-04-13 | 2013-05-13 | F. Hoffmann-La Roche Ag | Anticuerpos anti-P-selectina |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
CN105315373B (zh) | 2005-05-09 | 2018-11-09 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
US8219149B2 (en) | 2005-06-29 | 2012-07-10 | Nokia Corporation | Mobile communication terminal |
KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
EP2016101A2 (en) | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
CA2709847C (en) | 2008-01-07 | 2018-07-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
MX2010008786A (es) | 2008-02-11 | 2010-12-01 | Curetech Ltd | Anticuerpos monoclonales para tratamiento de tumores. |
WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
WO2010027828A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
SG196798A1 (en) * | 2008-12-09 | 2014-02-13 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
CA2778714C (en) | 2009-11-24 | 2018-02-27 | Medimmune Limited | Targeted binding agents against b7-h1 |
KR20230070054A (ko) | 2013-03-15 | 2023-05-19 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
EP3004877A4 (en) * | 2013-06-06 | 2017-04-19 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms |
WO2015036499A1 (en) | 2013-09-11 | 2015-03-19 | Medimmune Limited | Anti-b7-h1 antibodies for treating tumors |
KR20240033088A (ko) | 2013-09-20 | 2024-03-12 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하기 위한 항-lag-3 항체 및 항-pd-1 항체의 조합물 |
WO2016034718A1 (en) | 2014-09-05 | 2016-03-10 | Medimmune Limited | Methods for identifying patients responsive to anti-pd-l1 antibody therapy using markers (cxcl9, krt8.trim29, and ifngamma) |
WO2016183326A1 (en) | 2015-05-12 | 2016-11-17 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
-
2016
- 2016-05-12 WO PCT/US2016/032112 patent/WO2016183326A1/en active Application Filing
- 2016-05-12 MX MX2017014381A patent/MX2017014381A/es unknown
- 2016-05-12 EP EP16724821.0A patent/EP3294770B2/en active Active
- 2016-05-12 AU AU2016262074A patent/AU2016262074A1/en not_active Abandoned
- 2016-05-12 IL IL255312A patent/IL255312B/en unknown
- 2016-05-12 EP EP20191243.3A patent/EP3783029A1/en active Pending
- 2016-05-12 IL IL295002A patent/IL295002A/en unknown
- 2016-05-12 RS RS20201469A patent/RS61152B1/sr unknown
- 2016-05-12 KR KR1020177031945A patent/KR20180008449A/ko not_active Application Discontinuation
- 2016-05-12 HU HUE16724821A patent/HUE051815T2/hu unknown
- 2016-05-12 CA CA2983282A patent/CA2983282A1/en active Pending
- 2016-05-12 DK DK16724821.0T patent/DK3294770T3/da active
- 2016-05-12 LT LTEP16724821.0T patent/LT3294770T/lt unknown
- 2016-05-12 PT PT167248210T patent/PT3294770T/pt unknown
- 2016-05-12 ES ES16724821T patent/ES2835866T3/es active Active
- 2016-05-12 SI SI201631013T patent/SI3294770T1/sl unknown
- 2016-05-12 JP JP2017558454A patent/JP7048319B2/ja active Active
- 2016-05-12 CN CN201680031772.9A patent/CN107667119A/zh active Pending
-
2017
- 2017-10-19 US US15/787,988 patent/US20180030138A1/en not_active Abandoned
- 2017-11-09 MX MX2023002251A patent/MX2023002251A/es unknown
-
2018
- 2018-07-31 HK HK18109832.3A patent/HK1250376A1/zh unknown
-
2020
- 2020-11-27 HR HRP20201900TT patent/HRP20201900T1/hr unknown
-
2021
- 2021-11-26 US US17/535,898 patent/US20220073623A1/en active Pending
-
2022
- 2022-02-01 JP JP2022013871A patent/JP2022078021A/ja active Pending
- 2022-05-24 AU AU2022203501A patent/AU2022203501A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2018520996A (ja) | 2018-08-02 |
EP3294770B2 (en) | 2024-03-20 |
LT3294770T (lt) | 2020-12-28 |
CA2983282A1 (en) | 2016-11-17 |
DK3294770T3 (da) | 2020-12-07 |
ES2835866T3 (es) | 2021-06-23 |
AU2022203501A1 (en) | 2022-06-09 |
KR20180008449A (ko) | 2018-01-24 |
CN107667119A (zh) | 2018-02-06 |
HK1250376A1 (zh) | 2018-12-14 |
US20220073623A1 (en) | 2022-03-10 |
IL255312B (en) | 2022-08-01 |
IL255312A0 (en) | 2017-12-31 |
SI3294770T1 (sl) | 2021-01-29 |
EP3783029A1 (en) | 2021-02-24 |
JP7048319B2 (ja) | 2022-04-05 |
WO2016183326A1 (en) | 2016-11-17 |
HUE051815T2 (hu) | 2021-03-29 |
JP2022078021A (ja) | 2022-05-24 |
IL295002A (en) | 2022-09-01 |
RS61152B1 (sr) | 2020-12-31 |
PT3294770T (pt) | 2020-12-04 |
EP3294770B1 (en) | 2020-10-07 |
MX2017014381A (es) | 2018-03-02 |
US20180030138A1 (en) | 2018-02-01 |
EP3294770A1 (en) | 2018-03-21 |
AU2016262074A1 (en) | 2017-11-09 |
MX2023002251A (es) | 2023-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20201900T1 (hr) | Terapeutski i dijagnostički postupci kod raka | |
JP2018520996A5 (hr) | ||
JP2018521976A5 (hr) | ||
Liu et al. | Gastric cancer in the era of precision medicine | |
AU2021203547B2 (en) | Human mesothelin chimeric antigen receptors and uses thereof | |
JP2020099324A5 (hr) | ||
Asiedu et al. | TGFβ/TNFα-mediated epithelial–mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype | |
JP2019521641A5 (hr) | ||
JP2019535237A5 (hr) | ||
JP2017536842A5 (hr) | ||
JP2020516253A5 (hr) | ||
RU2017119231A (ru) | Способы и биомаркеры для прогнозирования эффективности и оценки лечения агонистом ох40 | |
Lee et al. | Current and emerging biomarkers in metastatic colorectal cancer | |
JP2018526323A5 (hr) | ||
JP2016520520A5 (hr) | ||
WO2014012007A4 (en) | Rspo3 binding agents and uses thereof | |
JP2019515670A5 (hr) | ||
JP2016539083A5 (hr) | ||
JP2012514473A5 (hr) | ||
US11779604B2 (en) | Antibodies, combinations comprising antibodies, biomarkers, uses and methods | |
Onstenk et al. | The use of circulating tumor cells in guiding treatment decisions for patients with metastatic castration-resistant prostate cancer | |
CN107090503B (zh) | 探针组合物、基因捕获芯片、试剂盒及其应用 | |
CN115087749A (zh) | 用于通过分析循环肿瘤dna进行分子疾病评定的方法和系统 | |
CN112442120A (zh) | 抗严重急性呼吸系统综合征ii型冠状病毒sars-cov-2的中和抗体 | |
Chao et al. | Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma |